Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 4Ureteral Neoplasms 2Urologic Neoplasms 1Urethral Neoplasms 1Peripheral Nervous System Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Carcinoma in Situ 1

Interventions

enfortumab vedotin 1durvalumab 1cemiplimab 1advexin 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Nivolumab 1Magnetic Resonance Imaging 1Histamine Antagonists 1Electrocardiography 1Diphenhydramine 1Cystoscopy 1Cholecalciferol 1Blood Specimen Collection 1Acetaminophen 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma in Situ × enfortumab vedotin × Clear all
NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Astellas Pharma Inc

Phase 1 Terminated
37 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡